Luca Issi
Stock Analyst at RBC Capital
(1.96)
# 1,306
Out of 4,653 analysts
160
Total ratings
37.5%
Success rate
-9.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Outperform | $16 → $14 | $6.80 | +105.88% | 4 | Nov 6, 2024 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Outperform | $77 | $48.71 | +58.08% | 3 | Nov 6, 2024 | |
| VERV Verve Therapeutics | Maintains: Outperform | $20 → $17 | $5.79 | +193.61% | 6 | Nov 6, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Sector Perform | $53 | $49.79 | +6.45% | 12 | Nov 6, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $25 → $24 | $28.25 | -15.04% | 2 | Nov 6, 2024 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $27 → $24 | $27.50 | -12.73% | 6 | Nov 6, 2024 | |
| EDIT Editas Medicine | Maintains: Sector Perform | $8 → $5 | $2.96 | +68.92% | 7 | Nov 5, 2024 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $12 → $10 | $7.56 | +32.28% | 6 | Nov 5, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $300 | $264.60 | +13.38% | 23 | Nov 1, 2024 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Sector Perform | $80 | $66.66 | +20.01% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $15.69 | -4.40% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $105 | $55.01 | +90.87% | 6 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $37.78 | +85.28% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $21.63 | +94.17% | 7 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $75 | $42.14 | +77.98% | 12 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $16.11 | +235.20% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $0.38 | +962.98% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $7.64 | +214.14% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $7.04 | +27.84% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.20 | +536.36% | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $7.71 | +418.81% | 5 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.72 | +267.65% | 7 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $2.44 | -18.03% | 5 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $20 → $35 | $10.67 | +228.02% | 7 | Mar 8, 2024 |
uniQure
Nov 6, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $6.80
Upside: +105.88%
Ultragenyx Pharmaceutical
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $48.71
Upside: +58.08%
Verve Therapeutics
Nov 6, 2024
Maintains: Outperform
Price Target: $20 → $17
Current: $5.79
Upside: +193.61%
CRISPR Therapeutics AG
Nov 6, 2024
Reiterates: Sector Perform
Price Target: $53
Current: $49.79
Upside: +6.45%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Sector Perform
Price Target: $25 → $24
Current: $28.25
Upside: -15.04%
Beam Therapeutics
Nov 6, 2024
Maintains: Sector Perform
Price Target: $27 → $24
Current: $27.50
Upside: -12.73%
Editas Medicine
Nov 5, 2024
Maintains: Sector Perform
Price Target: $8 → $5
Current: $2.96
Upside: +68.92%
Adverum Biotechnologies
Nov 5, 2024
Maintains: Sector Perform
Price Target: $12 → $10
Current: $7.56
Upside: +32.28%
Alnylam Pharmaceuticals
Nov 1, 2024
Reiterates: Outperform
Price Target: $300
Current: $264.60
Upside: +13.38%
BioMarin Pharmaceutical
Oct 30, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $66.66
Upside: +20.01%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $15.69
Upside: -4.40%
Oct 21, 2024
Maintains: Outperform
Price Target: $95 → $105
Current: $55.01
Upside: +90.87%
Sep 26, 2024
Reiterates: Outperform
Price Target: $70
Current: $37.78
Upside: +85.28%
Sep 26, 2024
Reiterates: Outperform
Price Target: $42
Current: $21.63
Upside: +94.17%
Sep 19, 2024
Reiterates: Sector Perform
Price Target: $75
Current: $42.14
Upside: +77.98%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $16.11
Upside: +235.20%
Aug 15, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $0.38
Upside: +962.98%
Aug 13, 2024
Reiterates: Outperform
Price Target: $24
Current: $7.64
Upside: +214.14%
Aug 13, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $7.04
Upside: +27.84%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $2.20
Upside: +536.36%
Jul 22, 2024
Reiterates: Outperform
Price Target: $40
Current: $7.71
Upside: +418.81%
Mar 15, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.72
Upside: +267.65%
Mar 14, 2024
Reiterates: Sector Perform
Price Target: $2
Current: $2.44
Upside: -18.03%
Mar 8, 2024
Upgrades: Outperform
Price Target: $20 → $35
Current: $10.67
Upside: +228.02%